BMS' Dolan in the hot seat over Plavix

Some investors in Bristol-Myers Squibb are particularly unhappy with CEO Peter Dolan, whose tenure has been marked by financial scandals and--even more importantly--the loss of its exclusive control of Plavix five years ahead of schedule.

- read the article on Dolan from The Wall Street Journal (sub. req.)